Actinogen Medical Limited (ATGGF) Research

Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system. Its development focuses on addressing Alzheimer's disease, cognitive impairment associated with depression, and the anxiety, sleep, and behavioral challenges seen in fragile X syndrome. Founded in 1999, the company, based in Sydney, Australia, operated as Actinogen Limited until its name change to Actinogen Medical Limited in November 2015.

Market snapshot

Symbol
ATGGF
Price
$0.00
Day change
0.00%
Market cap
$125.6M
P/E ratio
-6.03x
52-week range
0.0008-0.04
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BioStem Technologies, Inc. (BSEM)
  • Calliditas Therapeutics Ab (CLTEF)
  • Helix BioPharma Corp. (HBPCF)
  • Amplia Therapeutics Limited (INNMF)
  • Nicox S.A. (NICXF)
  • IXICO plc (PHYOF)
  • Alterity Therapeutics Limited (PRNAF)
  • MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY)

Open Actinogen Medical Limited (ATGGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.